Patent: 9,321,846
✉ Email this page to a colleague
Summary for Patent: 9,321,846
Title: | Compositions and methods comprising binding proteins for adalimumab |
Abstract: | Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-.alpha. and was developed to treat TNF-.alpha. mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab. |
Inventor(s): | Kaymakcalan; Zehra (Westborough, MA), Xiong; Limin (Shrewsbury, MA) |
Assignee: | ABBVIE BIOTECHNOLOGY LTD. (Hamilton, BM) |
Application Number: | 14/630,322 |
Patent Claims: | see list of patent claims |
Details for Patent 9,321,846
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 12/31/2002 | ⤷ Try a Trial | 2027-08-28 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 02/21/2008 | ⤷ Try a Trial | 2027-08-28 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 04/24/2013 | ⤷ Try a Trial | 2027-08-28 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 09/23/2014 | ⤷ Try a Trial | 2027-08-28 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |